Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9824|17|1-2|100-108

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.17, Iss.1-2, 2003-12, pp. : 100-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Smoking and Response to Cholinesterase Inhibitor Therapy in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 1, 2004-12 ,pp. : 11-14

Karger

Access to resources Recommend Favorite

Beyond the Cholinergic Hypothesis: The Effect of Metrifonate and Other Cholinesterase Inhibitors on Neuropsychiatric Symptoms in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 9, Iss. 2, 1998-07 ,pp. : 8-14

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Cholinesterase Inhibitor Affects the Amyloid Precursor Protein Isoforms in Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 5-6, 2005-04 ,pp. : 345-348

Karger

Access to resources Recommend Favorite

Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition

By  

European Neurology, Vol. 47, Iss. 1, 2002-01 ,pp. : 64-70

Karger

Access to resources Recommend Favorite